Filing Details

Accession Number:
0001140361-21-011505
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-04-05 09:02:22
Reporting Period:
2021-04-01
Accepted Time:
2021-04-05 09:02:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1484612 Outset Medical Inc. OM () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1218702 Keith D Grossman 3052 Orchard Drive
San Jose CA 95134
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-04-01 2,592 $1.11 2,592 No 4 M Direct
Common Stock Disposition 2021-04-01 2,592 $55.06 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2021-04-01 2,592 $0.00 2,592 $1.11
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
82,325 2024-06-16 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 11,604 Indirect Held by The D. Keith and Hallie H. Grossman Family Living Trust
Footnotes
  1. These shares of common stock of the Issuer ("Shares") are held directly by The D. Keith and Hallie H. Grossman Family Living Trust, for which the reporting person and his spouse serve as trustees.
  2. This option vested 25% on April 15, 2015, and then in 36 equal monthly installments thereafter.
  3. The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $54.78 to $55.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3).
  4. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020.
  5. This Form 4 corrects the expiration date previously reported as April 16, 2024 on the Form 3 filed on September 14, 2020.